BlackRock Inc. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$391,448,590
-18.6%
7,514,851
-1.0%
0.01%
-15.4%
Q2 2023$480,666,361
+22.1%
7,591,067
+4.4%
0.01%
+8.3%
Q1 2023$393,607,252
-0.2%
7,268,832
-2.4%
0.01%0.0%
Q4 2022$394,262,519
+19.3%
7,450,161
+4.9%
0.01%
+9.1%
Q3 2022$330,459,000
-17.9%
7,102,050
+0.8%
0.01%
-15.4%
Q2 2022$402,320,000
+1.6%
7,048,357
+8.9%
0.01%
+18.2%
Q1 2022$395,924,000
+32.2%
6,470,417
+13.1%
0.01%
+37.5%
Q4 2021$299,476,000
+40.0%
5,721,766
-0.3%
0.01%
+33.3%
Q3 2021$213,852,000
-8.4%
5,736,396
+0.3%
0.01%0.0%
Q2 2021$233,443,000
+11.7%
5,718,849
-7.1%
0.01%0.0%
Q1 2021$208,946,000
+11.4%
6,158,133
+4.4%
0.01%0.0%
Q4 2020$187,575,000
+38.7%
5,898,568
+11.9%
0.01%
+20.0%
Q3 2020$135,285,000
+5.3%
5,272,216
+5.3%
0.01%0.0%
Q2 2020$128,528,000
+88.4%
5,006,942
+12.8%
0.01%
+66.7%
Q1 2020$68,209,000
-49.2%
4,437,785
+13.5%
0.00%
-40.0%
Q4 2019$134,169,000
+351.6%
3,910,511
-1.7%
0.01%
+400.0%
Q3 2019$29,708,000
-41.8%
3,977,031
+1.1%
0.00%
-50.0%
Q2 2019$51,055,000
+8.9%
3,933,274
+2.2%
0.00%0.0%
Q1 2019$46,884,000
+2.8%
3,849,211
-3.9%
0.00%0.0%
Q4 2018$45,614,000
-46.5%
4,004,666
+1.9%
0.00%
-50.0%
Q3 2018$85,243,000
+27.1%
3,928,310
+3.5%
0.00%
+33.3%
Q2 2018$67,058,000
-15.1%
3,794,986
+1.1%
0.00%
-25.0%
Q1 2018$79,004,000
+36.3%
3,753,130
-6.2%
0.00%
+33.3%
Q4 2017$57,962,000
+11.5%
4,002,920
+21.5%
0.00%0.0%
Q3 2017$51,977,000
+9.1%
3,293,872
-14.1%
0.00%0.0%
Q2 2017$47,641,000
-18.0%
3,835,751
+7.3%
0.00%0.0%
Q1 2017$58,093,000
+25950.7%
3,574,983
+24047.1%
0.00%
Q4 2016$223,000
+3.2%
14,805
+4.2%
0.00%
Q3 2016$216,000
-94.7%
14,215
-86.3%
0.00%
-100.0%
Q2 2016$4,038,000
+41.6%
104,029
+1.4%
0.01%
+20.0%
Q1 2016$2,852,000
-47.8%
102,574
+1.0%
0.01%
-37.5%
Q4 2015$5,461,000
+17.5%
101,526
-12.5%
0.01%
+14.3%
Q3 2015$4,646,000
+272.0%
116,014
+196.6%
0.01%
+250.0%
Q2 2015$1,249,000
-46.3%
39,114
-59.8%
0.00%
-33.3%
Q1 2015$2,324,000
+35.4%
97,3140.0%0.00%
+50.0%
Q4 2014$1,717,000
+28.7%
97,3140.0%0.00%0.0%
Q3 2014$1,334,000
-24.8%
97,314
-7.5%
0.00%
-33.3%
Q2 2014$1,774,000
-6.9%
105,214
+0.4%
0.00%0.0%
Q1 2014$1,905,000104,8000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders